237 related articles for article (PubMed ID: 30207285)
41. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.
Shi JX; Qin JJ; Ye H; Wang P; Wang KJ; Zhang JY
Expert Rev Mol Diagn; 2015 Jun; 15(6):829-52. PubMed ID: 25959246
[TBL] [Abstract][Full Text] [Related]
42. Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients.
Cressey R; Pimpa S; Chewaskulyong B; Lertprasertsuke N; Saeteng S; Tayapiwatana C; Kasinrerk W
BMC Biotechnol; 2008 Feb; 8():16. PubMed ID: 18284706
[TBL] [Abstract][Full Text] [Related]
43. High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.
Luo R; Zheng C; Song W; Tan Q; Shi Y; Han X
Cancer Sci; 2022 Feb; 113(2):770-783. PubMed ID: 34843149
[TBL] [Abstract][Full Text] [Related]
44. BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer.
Pilyugin M; Ratajska M; Stukan M; Concin N; Zeillinger R; Irminger-Finger I
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34201956
[TBL] [Abstract][Full Text] [Related]
45. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
Zhang Z; Bast RC; Yu Y; Li J; Sokoll LJ; Rai AJ; Rosenzweig JM; Cameron B; Wang YY; Meng XY; Berchuck A; Van Haaften-Day C; Hacker NF; de Bruijn HW; van der Zee AG; Jacobs IJ; Fung ET; Chan DW
Cancer Res; 2004 Aug; 64(16):5882-90. PubMed ID: 15313933
[TBL] [Abstract][Full Text] [Related]
46. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
Berek JS; Bast RC
Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006
[TBL] [Abstract][Full Text] [Related]
47. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
[TBL] [Abstract][Full Text] [Related]
48. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
[TBL] [Abstract][Full Text] [Related]
49. Development of a novel multiplex beads-based assay for autoantibody detection for colorectal cancer diagnosis.
Villar-Vázquez R; Padilla G; Fernández-Aceñero MJ; Suárez A; Fuente E; Pastor C; Calero M; Barderas R; Casal JI
Proteomics; 2016 Apr; 16(8):1280-90. PubMed ID: 26915739
[TBL] [Abstract][Full Text] [Related]
50. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
51. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
[TBL] [Abstract][Full Text] [Related]
52. Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer.
Pedersen JW; Gentry-Maharaj A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Pedersen AE; Jacobs I; Menon U; Wandall HH
Br J Cancer; 2013 Jan; 108(1):107-14. PubMed ID: 23169294
[TBL] [Abstract][Full Text] [Related]
53. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
[TBL] [Abstract][Full Text] [Related]
54. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
[TBL] [Abstract][Full Text] [Related]
55. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
56. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.
Gorelik E; Landsittel DP; Marrangoni AM; Modugno F; Velikokhatnaya L; Winans MT; Bigbee WL; Herberman RB; Lokshin AE
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):981-7. PubMed ID: 15824174
[TBL] [Abstract][Full Text] [Related]
57. Validation of serum biomarkers for detection of early-stage ovarian cancer.
Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
[TBL] [Abstract][Full Text] [Related]
58. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
[TBL] [Abstract][Full Text] [Related]
59. Advances in the early detection of ovarian cancer: How to hear the whispers early.
Cesario S
Nurs Womens Health; 2010 Jun; 14(3):222-34. PubMed ID: 20579298
[No Abstract] [Full Text] [Related]
60. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.
Chapman CJ; Healey GF; Murray A; Boyle P; Robertson C; Peek LJ; Allen J; Thorpe AJ; Hamilton-Fairley G; Parsy-Kowalska CB; MacDonald IK; Jewell W; Maddison P; Robertson JF
Tumour Biol; 2012 Oct; 33(5):1319-26. PubMed ID: 22492236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
